Pharma Industry News

FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder

Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]